<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Res Ther</journal-id><journal-title-group><journal-title>Alzheimer's Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="epub">1758-9193</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25478030</article-id><article-id pub-id-type="pmc">4255553</article-id><article-id pub-id-type="publisher-id">s13195-014-0072-3</article-id><article-id pub-id-type="doi">10.1186/s13195-014-0072-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Biomarkers in biological fluids for dementia with Lewy bodies</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Schade</surname><given-names>Sebastian</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>sebastian.schade@stud.uni-goettingen.de</email></contrib><contrib contrib-type="author" corresp="yes" id="A2"><name><surname>Mollenhauer</surname><given-names>Brit</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I4">4</xref><email>brit.mollenhauer@paracelsus-kliniken.de</email></contrib></contrib-group><aff id="I1"><label>1</label>Paracelsus-Elena-Klinik, Klinikstra&#x000df;e 16, Kassel, D-34128, Germany</aff><aff id="I2"><label>2</label>Department of Clinical Neurophysiology, University Medical Center, Georg-August University, Robert-Koch Stra&#x000df;e 40, G&#x000f6;ttingen, 37075, Germany</aff><aff id="I3"><label>3</label>Department of Neurosurgery, University Medical Center, Georg-August University, Robert-Koch Stra&#x000df;e 40, G&#x000f6;ttingen, 37075, Germany</aff><aff id="I4"><label>4</label>Department of Neuropathology, University Medical Center, Georg-August University, Robert-Koch Stra&#x000df;e 40, G&#x000f6;ttingen, 37075, Germany</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>16</day><month>10</month><year>2014</year></pub-date><volume>6</volume><issue>5</issue><fpage>72</fpage><lpage>72</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Schade and Mollenhauer; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Schade and Mollenhauer; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>The licensee has exclusive rights to distribute this article, in any medium, for 12 months following its publication. After this time, the article is available under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://alzres.com/content/6/5/72"/><abstract><p>Dementia with Lewy bodies (DLB) has become the second most common neurodegenerative dementia due to demographic ageing. Differential diagnosis is still troublesome especially in early stages of the disease, since there is a great clinical and neuropathological overlap primarily with Alzheimer&#x02019;s disease and Parkinson&#x02019;s disease. Therefore, more specific biomarkers, not only for scientific reasons but also for clinical therapeutic decision-making, are urgently needed. In this review, we summarize the knowledge on fluid biomarkers for DLB, derived predominantly from cerebrospinal fluid. We discuss the value of well-defined markers (&#x003b2;-amyloid, (phosphorylated) tau, &#x003b1;-synuclein) as well as some promising &#x02018;upcoming&#x02019; substances, which still have to be further evaluated.</p></abstract></article-meta></front><body><sec><title>1
Introduction</title><p>The isolation and successful detection of soluble &#x003b2;-amyloid (A&#x003b2;) from biological fluids in 1992 [<xref ref-type="bibr" rid="B1">1</xref>] revolutionized our knowledge of the connection between molecular pathology and cerebrospinal fluid (CSF) biomarkers. The progressing elucidation of the underlying and overlapping molecular pathologies of several neurodegenerative diseases, including Alzheimer&#x02019;s disease (AD) and Parkinson&#x02019;s disease (PD), has resulted in new biomarkers, which are urgently needed for more accurate diagnosis and as possible endpoints for clinical trials with future neuropreventive strategies. Thanks to vigorous defining criteria, the stratification of dementia with Lewy-bodies (DLB) as a molecular and clinical &#x02018;in-between&#x02019; disorder has been pursued, but it still has clinical and neuropathological overlap with AD and PD [<xref ref-type="bibr" rid="B2">2</xref>],[<xref ref-type="bibr" rid="B3">3</xref>], which makes its early diagnosis difficult. While hallucinations in AD predict the coincidence of DLB with a specificity of 100% [<xref ref-type="bibr" rid="B4">4</xref>], the presence of non-motor symptoms, decreased dopamine transporter imaging [<xref ref-type="bibr" rid="B5">5</xref>] and response to dopaminergic therapy does not help to separate DLB from PD since only about 36% of subjects can be clinically classified as &#x02018;responders&#x02019; using the L-dopa challenge [<xref ref-type="bibr" rid="B6">6</xref>],[<xref ref-type="bibr" rid="B7">7</xref>].</p><p>The quantification of A&#x003b2;1-42 in CSF in combination with total and/or phosphorylated tau protein was recently (together with positron emission tomography and structural magnetic resonance imaging) included in proposed research criteria for the clinical diagnosis of AD [<xref ref-type="bibr" rid="B8">8</xref>]. Here, reduced A&#x003b2;1-42 and increased total/phosphorylated tau protein in CSF correlate with neuropathologic features of the disease - that is, A&#x003b2; plaques and neurofibrillary tangles and neuronal loss - as well as clinical symptoms and disease intensity [<xref ref-type="bibr" rid="B9">9</xref>]. This CSF signature is a good predictor for cognitive decline in mild cognitive impairment [<xref ref-type="bibr" rid="B10">10</xref>] with high predictive value for identifying converters into overt dementia [<xref ref-type="bibr" rid="B11">11</xref>].</p><p>In PD, the underlying pathology is characterized by presynaptic &#x003b1;-synuclein (aSyn) aggregates and synapse rarefaction. Cognitive decline in PD occurs due to various reasons leading to destruction of essential networks [<xref ref-type="bibr" rid="B12">12</xref>]. The main question of whether and how much AD and aSyn pathology each contribute to cognitive decline in PD remains disputable [<xref ref-type="bibr" rid="B13">13</xref>]. A majority of DLB patients show increased cortical <sup>11</sup>C-PIB binding, similar to AD [<xref ref-type="bibr" rid="B14">14</xref>],[<xref ref-type="bibr" rid="B15">15</xref>]. This suggests that DLB is actually a dementia associated with both aSyn and A&#x003b2; pathology, thereby possibly explaining its aggressive nature. PD with dementia (PDD), in contrast, shows a reduced prevalence of amyloid plaques and lower levels of cortical <sup>11</sup>C-PIB binding than DLB [<xref ref-type="bibr" rid="B14">14</xref>]-[<xref ref-type="bibr" rid="B16">16</xref>]. This finding suggests that the dementia of PD subjects is more likely due to a specific aSyn pathology rather than only an overlap of other pathologies, in agreement with post-mortem observations [<xref ref-type="bibr" rid="B17">17</xref>],[<xref ref-type="bibr" rid="B18">18</xref>]. Others suggest, however, that the neuropathological correlate of PDD is a combination of different pathologies rather than the severity of any single pathology [<xref ref-type="bibr" rid="B3">3</xref>]. In addition, it has been proposed that the presence of A&#x003b2; triggers cognitive decline and dementia in PDD and DLB, but does not directly determine its nature [<xref ref-type="bibr" rid="B19">19</xref>]. In this context, it should be highlighted that incidental A&#x003b2; can be detected on occasion in healthy controls as well as in older subjects with PD [<xref ref-type="bibr" rid="B15">15</xref>], and decreased levels of CSF A&#x003b2;1-42 have been observed in recently diagnosed PD patients [<xref ref-type="bibr" rid="B20">20</xref>] and in patients with and without cognitive decline [<xref ref-type="bibr" rid="B21">21</xref>],[<xref ref-type="bibr" rid="B22">22</xref>]; this suggests that amyloid pathology does not have a single causative role in dementia. Furthermore, it has been shown that PD cases without dementia, but progression of cortical amyloid, show a faster cognitive deterioration than patients who are without A&#x003b2; deposits at baseline [<xref ref-type="bibr" rid="B23">23</xref>]. This is supported by a recent study that showed that low levels of CSF A&#x003b2;1-42 predict early-onset cognitive decline [<xref ref-type="bibr" rid="B24">24</xref>].</p><p>Thus, one current major problem is the overlapping neuropathology and the as yet incompletely understood molecular constituents of the pathological changes. It is expected that in the next years many more neuropathological entities will be identified and characterized at the molecular level, which will also influence our thinking of clinical phenotyping and the selection of biomarker candidates in the future [<xref ref-type="bibr" rid="B25">25</xref>].</p></sec><sec><title>2
Biomarkers in dementia with Lewy bodies</title><p>In addition to imaging biomarkers (see article by Mak and colleagues within this special series [<xref ref-type="bibr" rid="B26">26</xref>]), biomarkers in DLB include functional marker candidates, like electroencephalography slowing [<xref ref-type="bibr" rid="B27">27</xref>] and the detection of rapid eye movement sleep behaviour disorder and other sleep disturbances with polysomnography [<xref ref-type="bibr" rid="B28">28</xref>].</p><p>Dopamine transporter imaging studies are helpful in the differential diagnosis of AD, but are expensive and not widely available. A biological fluid marker would be more widely available (when shipped to a central laboratory), cheap, and have low safety concerns. Optimal marker candidates reflect a process proximal to the specific pathology; therefore, most studies on neurodegenerative disorders rely on marker candidates in the CSF. The &#x02018;CSF analytic area&#x02019; comprises the area of the brain directly contributing to CSF composition, which incorporates the basal ganglia and the brainstem as main sites of interest in movement disorders. aSyn pathology in DLB (and PD) has also been shown in the periphery [<xref ref-type="bibr" rid="B29">29</xref>], however, which could enable the detection of a marker in peripheral biological fluids; for example, in blood or saliva [<xref ref-type="bibr" rid="B30">30</xref>]. So far, studies have been discrepant and need further validation (see below).</p><sec><title>2.1 Cerebrospinal fluid biomarkers in dementia with Lewy bodies</title><p>The composition and alteration of CSF proteins, which might be disease-specific, underlines the value of CSF analysis as a diagnostic tool. Nevertheless, known and potential confounding factors need to be taken into account in any biological fluid study, such as protease activity, blood contamination - which occurs in 10 to 20% of lumbar punctures - and adhesion, especially of lipophilic proteins to certain external surfaces like polypropylene and glass. The adherence of standard operating procedures is essential to avoid false positive or negative findings.</p></sec><sec><title>2.2 Alzheimer&#x02019;s disease biomarkers in dementia with Lewy bodies</title><p>The combination of decreased A&#x003b2; peptides and increased total/phosphorylated tau protein in CSF of AD subjects has shown diagnostic sensitivity and specificity above 80% in most studies [<xref ref-type="bibr" rid="B9">9</xref>].</p><p>Enzymatic cleavage of the 120&#x000a0;kDa transmembrane amyloid precursor protein leads to different fragments of the A&#x003b2; peptide [<xref ref-type="bibr" rid="B31">31</xref>]. A&#x003b2; seems to be important for the processing of information between neurons and is variably prone to aggregate and form plaques [<xref ref-type="bibr" rid="B32">32</xref>]. Amyloid plaques are found in the brain of patients with AD and DLB [<xref ref-type="bibr" rid="B31">31</xref>],[<xref ref-type="bibr" rid="B33">33</xref>] and contain primarily carboxy-terminally elongated forms of A&#x003b2; peptides, such as the fragment A&#x003b2;1-42.</p><p>As in AD, CSF levels of A&#x003b2;1-42 in DLB are regularly decreased compared to non-demented controls [<xref ref-type="bibr" rid="B34">34</xref>]. The correlation of decreased CSF A&#x003b2; values was shown by <italic>in vivo</italic> brain amyloid load in AD [<xref ref-type="bibr" rid="B35">35</xref>] but also appeared to be non-specifically decreased in other disorders without plaque pathology [<xref ref-type="bibr" rid="B36">36</xref>], which might be due to interindividual differences in the amount of amyloidogenic amyloid precursor protein processing. Attempts to normalize A&#x003b2;1-42 concentrations to A&#x003b2;1-40 (A&#x003b2;1-42/A&#x003b2;1-40 ratio) have been promising in terms of differentiating AD from DLB when compared with measuring these biomarkers individually [<xref ref-type="bibr" rid="B37">37</xref>]. Nevertheless, most studies could not define valuable cutoff scores to distinguish AD and DLB [<xref ref-type="bibr" rid="B38">38</xref>],[<xref ref-type="bibr" rid="B39">39</xref>], including one large autopsy study [<xref ref-type="bibr" rid="B40">40</xref>]. One reason might be the heterogeneity and possible interaction of neuropathological alterations in DLB. At least one study showed significantly lower CSF A&#x003b2;1-42 in DLB patients with senile plaques compared with DLB patients without senile plaques [<xref ref-type="bibr" rid="B41">41</xref>]. Another reason could be that a correlation between phosphorylated tau protein in CSF and its neuropathological equivalent (neurofibrillary tangles) was not found in patients with DLB [<xref ref-type="bibr" rid="B41">41</xref>].</p><p>Other fragments, isoforms and posttranslational modifications of A&#x003b2; peptides have also been proposed as CSF biomarkers for DLB. The oxidized version of A&#x003b2;1-40 (A&#x003b2;1-40<sup>ox</sup>), containing &#x003b1;-helical structures [<xref ref-type="bibr" rid="B42">42</xref>], has been shown to be increased in DLB patients compared with PDD patients and non-demented disease controls, which recently also has been shown in autopsy-proven AD and DLB [<xref ref-type="bibr" rid="B43">43</xref>]. This finding has been proposed to be a pathophysiological metabolism of A&#x003b2;1-40 specific to DLB, but needs to be replicated by independent groups and using alternative approaches. Other A&#x003b2; isoforms, such as A&#x003b2;1-37 and A&#x003b2; 1&#x02013;38, are still a focus of research, but need to be better characterized [<xref ref-type="bibr" rid="B42">42</xref>]. Further posttranslational modifications (for example, fragmented forms of A&#x003b2;) possibly reflecting more disease-specific changes are currently been investigated by different groups [<xref ref-type="bibr" rid="B44">44</xref>].</p><p>The natively unfolded microtubule-associated phosphoprotein 68&#x000a0;kDa tau is important for the stabilization of microtubules [<xref ref-type="bibr" rid="B45">45</xref>]. Neuronal cells in AD contain pairwise helical protein filaments (neurofibrillary tangles) [<xref ref-type="bibr" rid="B46">46</xref>],[<xref ref-type="bibr" rid="B47">47</xref>] that are insoluble, stable polymers of the low molecular weight tau protein [<xref ref-type="bibr" rid="B48">48</xref>].</p><p>Intracellular tau protein is elevated in CSF of AD subjects and excessively increases in conditions with rapid neuronal loss - for example, Creutzfeldt-Jakob disease. In DLB, levels of CSF tau protein are lower compared to AD [<xref ref-type="bibr" rid="B40">40</xref>] and higher compared to PD and PDD [<xref ref-type="bibr" rid="B49">49</xref>]. Interestingly, patients with a diagnosis of &#x02018;probable DLB&#x02019; according to the classification criteria [<xref ref-type="bibr" rid="B5">5</xref>] (which should be more accurate), tend to have even lower CSF tau protein levels [<xref ref-type="bibr" rid="B49">49</xref>].</p><p>Hyperphosphorylation of tau protein promotes its aggregation into neurofibrillary tangles. Some CSF studies have revealed better specificity for the discrimination of AD when using p-tau protein 181 rather than total tau protein [<xref ref-type="bibr" rid="B50">50</xref>]. Since the phosphorylation of tau protein in brain occurs to a lesser extent in DLB [<xref ref-type="bibr" rid="B51">51</xref>],[<xref ref-type="bibr" rid="B52">52</xref>], the quantification of phosphorylated tau species in CSF may serve as a specific marker to discriminate AD from DLB [<xref ref-type="bibr" rid="B50">50</xref>],[<xref ref-type="bibr" rid="B53">53</xref>]. Other phosphorylation sites of tau protein in CSF have been analyzed for their diagnostic value, showing similar results [<xref ref-type="bibr" rid="B54">54</xref>]-[<xref ref-type="bibr" rid="B57">57</xref>] (Table&#x000a0;<xref ref-type="table" rid="T1">1</xref>).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Sumary of neuropathologic, clinical, imaging and fluid markers in dementia with Lewy bodies, Parkinson&#x02019;s disease and Alzheimer&#x02019;s disease</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr valign="top"><th align="left" valign="top">&#x000a0;</th><th align="left" valign="top"><bold>AD</bold></th><th align="left" valign="top"><bold>AD and DLB</bold></th><th align="left" valign="top"><bold>DLB</bold></th><th align="left" valign="top"><bold>DLB and PD(D)</bold></th><th align="left" valign="top"><bold>PD</bold></th></tr></thead><tbody><tr valign="top"><td rowspan="2" align="left" valign="top"><bold>Neuropathology</bold><hr/></td><td rowspan="2" align="left" valign="top">&#x000a0;<hr/></td><td align="left" valign="top">Neurofibrillary tangles<hr/></td><td rowspan="2" align="left" valign="top">&#x000a0;<hr/></td><td rowspan="2" align="left" valign="top">Lewy bodies<hr/></td><td rowspan="2" align="left" valign="top">&#x000a0;<hr/></td></tr><tr valign="top"><td align="left" valign="top">Amyloid plaques<hr/></td></tr><tr valign="top"><td rowspan="3" align="left" valign="top"><bold>Clinical symptoms</bold><hr/></td><td rowspan="3" align="left" valign="top">&#x000a0;<hr/></td><td rowspan="3" align="left" valign="top">Cognitive decline<hr/></td><td rowspan="3" align="left" valign="top">Spontaneous hallucinations<hr/></td><td align="left" valign="top">Cognitive decline<hr/></td><td rowspan="3" align="left" valign="top">&#x000a0;<hr/></td></tr><tr valign="top"><td align="left" valign="top">RBD<hr/></td></tr><tr valign="top"><td align="left" valign="top">L-Dopa response<hr/></td></tr><tr valign="top"><td align="left" valign="top"><bold>Nuclear imaging</bold><hr/></td><td align="left" valign="top">&#x000a0;<hr/></td><td align="left" valign="top">PIB binding&#x02191;<hr/></td><td align="left" valign="top">&#x000a0;<hr/></td><td align="left" valign="top">DAT&#x02193;<hr/></td><td align="left" valign="top">&#x000a0;<hr/></td></tr><tr valign="top"><td rowspan="3" align="left" valign="top"><bold>CSF biomarkers</bold><hr/></td><td align="left" valign="top">tau &#x02191;<hr/></td><td align="left" valign="top">&#x003b2;-Amyloid 1&#x02013;42 &#x02193;<hr/></td><td align="left" valign="top">&#x003b2;-Amyloid 1-40<sup>ox</sup>&#x02191;<hr/></td><td align="left" valign="top">&#x003b1;-Synuclein&#x02193;<hr/></td><td align="left" valign="top">&#x003b1;-Synuclein&#x02193;<hr/></td></tr><tr valign="top"><td align="left" valign="top">p-tau &#x02191;<hr/></td><td align="left" valign="top">Soluble NG2&#x02193;<hr/></td><td align="left" valign="top">CART&#x02193;<hr/></td><td align="left" valign="top">Neurosin&#x02193;<hr/></td><td align="left" valign="top">Oligomeric &#x003b1;-synuclein&#x02191;<hr/></td></tr><tr valign="top"><td align="left" valign="top">&#x000a0;<hr/></td><td align="left" valign="top">&#x000a0;<hr/></td><td align="left" valign="top">NF&#x02191;<hr/></td><td align="left" valign="top">&#x000a0;<hr/></td><td align="left" valign="top">&#x000a0;<hr/></td></tr><tr valign="top"><td rowspan="2" align="left" valign="top"><bold>Serum biomarkers</bold></td><td rowspan="2" align="left" valign="top">&#x000a0;</td><td rowspan="2" align="left" valign="top">&#x000a0;</td><td align="left" valign="top">H-FABP &#x02191;<hr/></td><td rowspan="2" align="left" valign="top">&#x000a0;</td><td rowspan="2" align="left" valign="top">&#x000a0;</td></tr><tr valign="top"><td align="left" valign="top">Ca/Mg&#x02191;</td></tr></tbody></table><table-wrap-foot><p>AD, Alzheimer&#x02019; disease; CART, cocaine and amphetamine regulated transcript; CSF, cerebrospinal fluid; DAT, dopamine transporter imaging; DLB, dementia with Lewy bodies; H-FABP, heart-type fatty acid binding protein; NF, neurofilament; NG2, Neuron glia 2; PD, Parkinson&#x02019;s disease; PDD, Parkinson&#x02019;s disease with dementia; PIB, Pittsburgh compound B; p-tau, phosphorylated tau protein; RBD, REM sleep behaviour disorder.</p></table-wrap-foot></table-wrap></sec><sec><title>2.3 Parkinson&#x02019;s disease biomarkers in dementia with Lewy bodies</title><p>The 140 amino acid aSyn is predominantly expressed in the pre-synapses supporting the formation and transport of vesicles [<xref ref-type="bibr" rid="B58">58</xref>] and is the major constituent of Lewy bodies, the generally accepted pathological hallmark of PD and DLB, and it is also present in the glial cytoplasmic inclusions of multiple system atrophy [<xref ref-type="bibr" rid="B59">59</xref>],[<xref ref-type="bibr" rid="B60">60</xref>].</p><p>Full-length aSyn has been detected in extracellular biological fluids, including plasma, conditioned cell media and most recently saliva [<xref ref-type="bibr" rid="B61">61</xref>],[<xref ref-type="bibr" rid="B62">62</xref>]. The quantification of extracellular aSyn has been proposed as a potential biomarker for synuclein-related disorders: most investigators have shown a reduction of CSF total aSyn in the synuclein-related disorders PD, DLB and multiple system atrophy [<xref ref-type="bibr" rid="B63">63</xref>]-[<xref ref-type="bibr" rid="B65">65</xref>]. A rather small study, but one that strictly controlled several possible confounders (for example, blood contamination, diurnal variation, food intake, rostro-caudal CSF gradient, gender, age), showed contradictory results, with an increase of aSyn in DLB compared with healthy controls and AD patients [<xref ref-type="bibr" rid="B66">66</xref>]. These results need to be replicated, but possible confounding factors (for example, blood contamination, subject selection and technical/methodological differences, especially choosing the right antibodies to ensure accurate measurement of total aSyn rather than its fractions) should be even more rigorously taken into account when conducting further studies.</p><p>The underlying mechanism of decreasing CSF aSyn remains unclear to date, and could result from various scenarios, such as the reduction of aSyn release into the extracellular space due to intracellular aggregation; alteration of <italic>SNCA</italic> gene transcription [<xref ref-type="bibr" rid="B67">67</xref>], mRNA splicing [<xref ref-type="bibr" rid="B68">68</xref>] or protein processing [<xref ref-type="bibr" rid="B69">69</xref>]; a higher CSF flow with lower permeation of plasma aSyn into CSF; an enhanced clearance rate of aSyn from CSF [<xref ref-type="bibr" rid="B70">70</xref>]; or as yet unidentified factors or any combination of mechanisms [<xref ref-type="bibr" rid="B65">65</xref>]. Furthermore, aSyn might intracellularly aggregate in Lewy bodies and presynaptic terminals (thereby possibly decreasing the extracellular amount), since results from studies on aSyn in patients with AD have been somewhat heterogeneous, perhaps indicating a subgroup of AD patients with additional Lewy body pathology and a clear mismatch of high p-tau protein 181 and low aSyn CSF levels [<xref ref-type="bibr" rid="B71">71</xref>]. A possible explanation for increased CSF aSyn levels (in addition to the inverse of the mechanisms described above) might be that they partly reflect neuronal and/or axonal injury, which would be in line with a correlation of total tau values and aSyn in CSF samples of AD patients [<xref ref-type="bibr" rid="B71">71</xref>], although a correlation between aSyn levels and regional brain atrophy could not be detected [<xref ref-type="bibr" rid="B72">72</xref>].</p><p>Whereas methods for quantifying total aSyn detect mono- and oligomeric forms, an oligomer-specific aSyn assay has been established that uses the same monoclonal antibody for both capture and detection [<xref ref-type="bibr" rid="B73">73</xref>]. Oligomeric aSyn comprises up to 10% of the total aSyn content of CSF. Independent studies show an increase of CSF oligomeric aSyn in PD compared with AD, progressive supranuclear palsy and controls [<xref ref-type="bibr" rid="B73">73</xref>],[<xref ref-type="bibr" rid="B74">74</xref>]. Together with the reduced CSF total aSyn, the ratio of oligomeric to total aSyn had a sensitivity of 89.3% and a specificity of 90.6% for the diagnosis of PD in this study [<xref ref-type="bibr" rid="B74">74</xref>].</p><p>Further investigation of the specificity of the antibodies and total and oligomeric aSyn enzyme-linked immunoassay techniques are needed, as are independent studies on other posttranslationally modified aSyn species, studies quantifying CSF aSyn in longitudinal patient cohorts, as well as studies of aSyn in other biological fluids.</p><p>Neurosin, a protein suggested to cleave aSyn and thereby potentially with a major role in the pathomechanisms of diseases associated with aSyn pathology, was shown to be reduced in CSF of patients with synuclein-related disorders compared with healthy controls and patients with AD. The lowest levels have been found in patients with DLB, thereby offering a new option for a potential biomarker [<xref ref-type="bibr" rid="B75">75</xref>].</p><p>Other PD biomarkers in CSF have not yet been investigated in DLB, such as the multifunctional protein DJ-1 and its oxidized forms involved in many cellular processes [<xref ref-type="bibr" rid="B76">76</xref>]-[<xref ref-type="bibr" rid="B78">78</xref>], and other synaptic proteins.</p></sec><sec><title>2.4 Other potential biomarkers for dementia with Lewy bodies</title><sec><title>2.4.1 Neurofilaments</title><p>Neurofilaments (NFs) are involved in structural integrity and cell/organelle motility along the axons and determine axon calibre. CSF levels of NFs have been found to be elevated in DLB, but no significant differences have been observed in comparison with other dementias. Therefore, NFs seem to provide only a general hint of neuronal and axonal dysfunction without differential value for separating DLB from other disorders [<xref ref-type="bibr" rid="B79">79</xref>]. But data are still rare. In particular, subsets of NFs need to be evaluated further, since various types of neurons are affected in the different forms of dementia, perhaps meaning that different patterns of elevated NFs are potential biomarkers for differential diagnosis of dementias. Three different subunits of NF (light (NF-L), medium (NF-M) and heavy (NF-H)) have been defined. The filament is made up of one NF-L and either NF-M or NF-H arranged head to tail [<xref ref-type="bibr" rid="B80">80</xref>],[<xref ref-type="bibr" rid="B81">81</xref>].</p></sec><sec><title>2.4.2 Fatty acid-binding proteins</title><p>Fatty acid-binding proteins (FABPs) are a family of small intracellular proteins that facilitate the transport of fatty acids between the cell membrane and different organelles [<xref ref-type="bibr" rid="B82">82</xref>]. Lower levels of heart-type FABP have been reported in brains from patients with Down&#x02019;s syndrome and AD [<xref ref-type="bibr" rid="B83">83</xref>]. Serum FABP levels are elevated in a quite distinct manner in DLB [<xref ref-type="bibr" rid="B84">84</xref>],[<xref ref-type="bibr" rid="B85">85</xref>].</p></sec><sec><title>2.4.3 Other potential biomarkers</title><p>On the basis of stronger pathological involvement of dopaminergic and serotonergic pathways in DLB than in AD, several neurotransmitters and their metabolites have been investigated. Reduced levels of the metabolites homovanillic acid, 5- hydroxyindolacetic acid and 3-methoxy-4-hydroxyphenylethyleneglycol have been found in DLB compared with AD [<xref ref-type="bibr" rid="B86">86</xref>]. Especially the latter, in combination with total tau protein, p-tau and A&#x003b2;1-42, could increase the sensitivity and specificity of discriminating those entities [<xref ref-type="bibr" rid="B87">87</xref>].</p><p>The chondroitinase sulphate proteoglycan Neuron glia 2 is a proteoglycan involved in several basic cellular mechanisms of pericytes as well as oligodentrocyte progenitor cells and its soluble form can be detected in CSF. Lower levels of soluble Neuron glia 2 have been found in CSF of patients with AD and DLB, but not in patients with PD or PDD, thereby implicating some kind of association with the accumulation of A&#x003b2; rather than aSyn. Results are preliminary and mechanisms far from being understood, but further investigations seem to be worthwhile [<xref ref-type="bibr" rid="B88">88</xref>].</p><p>Cocaine and amphetamine regulated transcript is a neuropeptide which is expressed selectively in the hypothalamus and was recently found to be present at significantly reduced levels in the CSF of DLB patients compared with controls and patients with AD [<xref ref-type="bibr" rid="B89">89</xref>]. Further studies are needed to confirm these preliminary data resulting from a rather small patient sample. Similarly, elevated levels of calcium and magnesium in CSF as well as of magnesium in blood were found by a Swedish study group, which used mass spectrometry to compare DLB patients with healthy controls and patients with AD [<xref ref-type="bibr" rid="B90">90</xref>]. These findings have to be replicated by independent groups. It is noteworthy that following our growing knowledge of molecular genetics in the field of neurodegenerative diseases, there have been high expectations that some gene products (for example, DJ-1, glucocerebrosidase) might be of use as biomarkers. Unfortunately, results have been either heterogeneous or rare in terms of DLB [<xref ref-type="bibr" rid="B91">91</xref>].</p><p>Finally, new diagnostic proteins might be discovered by proteomic studies. So far, some &#x02018;protein peaks&#x02019; have been found as potential differential biomarkers, but these have either not been attributed to specific proteins [<xref ref-type="bibr" rid="B92">92</xref>] or have not been confirmed by further studies [<xref ref-type="bibr" rid="B93">93</xref>]. It is problematic that there is a lack of consistency across proteomic studies, which might be due to strong variations during sample preparation prior to the proteomic experiment itself (for example, degradation of proteins by storage material, contamination with blood) [<xref ref-type="bibr" rid="B94">94</xref>]. Therefore, standardized procedures are needed.</p></sec></sec></sec><sec><title>3
Conclusion</title><p>This review summarizes current studies on neurochemical marker candidates for DLB. Overall, it is clear that DLB is a disease &#x02018;in between&#x02019; AD and PD, which is supported by clinical, imaging, neuropathological and neurochemical studies. Biomarker candidates from the AD and PD fields have been tested in DLB, but only a few have been shown to more specifically reflect the underlying DLB. Most of the markers reflect neuropathological features, but as long our discrimination of PDD and DLB is based only on an arbitrary &#x02018;one-year rule&#x02019; without separation based on molecular pathology, biomarker studies with DLB subjects will be hampered [<xref ref-type="bibr" rid="B95">95</xref>].</p></sec><sec><title>4
Note</title><p>This article is part of a series on Lewy Body Dementia, edited by Ian McKeith and James Galvin. Other articles in this series can be found at <ext-link ext-link-type="uri" xlink:href="http://alzres.com/series/LewyBodyDementia">http://alzres.com/series/LewyBodyDementia</ext-link>.</p></sec><sec><title>Abbreviations</title><p>A&#x003b2;: &#x003b2;-amyloid</p><p>AD: Alzheimer&#x02019; disease</p><p>aSyn: &#x003b1;-synuclein</p><p>CSF: Cerebrospinal fluid</p><p>DLB: Dementia with Lewy bodies</p><p>FABP: Fatty acid-binding protein</p><p>NF: Neurofilament</p><p>PD: Parkinson&#x02019;s disease</p><p>PDD: Parkinson&#x02019;s disease with dementia</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Seubert</surname><given-names>P</given-names></name><name><surname>Vigo-Pelfrey</surname><given-names>C</given-names></name><name><surname>Esch</surname><given-names>F</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Dovey</surname><given-names>H</given-names></name><name><surname>Davis</surname><given-names>D</given-names></name><name><surname>Sinha</surname><given-names>S</given-names></name><name><surname>Schlossmacher</surname><given-names>M</given-names></name><name><surname>Whaley</surname><given-names>J</given-names></name><name><surname>Swindlehurst</surname><given-names>C</given-names></name><name><surname>McCormack</surname><given-names>R</given-names></name><name><surname>Wolfert</surname><given-names>R</given-names></name><name><surname>Selkoe</surname><given-names>D</given-names></name><name><surname>Lieberburg</surname><given-names>I</given-names></name><name><surname>Schenk</surname><given-names>D</given-names></name><article-title>Isolation and quantification of soluble Alzheimer&#x02019;s beta-peptide from biological fluids</article-title><source>Nature</source><year>1992</year><volume>359</volume><fpage>325</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1038/359325a0</pub-id><pub-id pub-id-type="pmid">1406936</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Noe</surname><given-names>E</given-names></name><name><surname>Marder</surname><given-names>K</given-names></name><name><surname>Bell</surname><given-names>KL</given-names></name><name><surname>Jacobs</surname><given-names>DM</given-names></name><name><surname>Manly</surname><given-names>JJ</given-names></name><name><surname>Stern</surname><given-names>Y</given-names></name><article-title>Comparison of dementia with Lewy bodies to Alzheimer&#x02019;s disease and Parkinson&#x02019;s disease with dementia</article-title><source>Mov Disord</source><year>2004</year><volume>19</volume><fpage>60</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1002/mds.10633</pub-id><pub-id pub-id-type="pmid">14743362</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Compta</surname><given-names>Y</given-names></name><name><surname>Parkkinen</surname><given-names>L</given-names></name><name><surname>O'Sullivan</surname><given-names>SS</given-names></name><name><surname>Vandrovcova</surname><given-names>J</given-names></name><name><surname>Holton</surname><given-names>JL</given-names></name><name><surname>Collins</surname><given-names>C</given-names></name><name><surname>Lashley</surname><given-names>T</given-names></name><name><surname>Kallis</surname><given-names>C</given-names></name><name><surname>Williams</surname><given-names>DR</given-names></name><name><surname>de Silva</surname><given-names>R</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name><name><surname>Revesz</surname><given-names>T</given-names></name><article-title>Lewy- and Alzheimer-type pathologies in Parkinson&#x02019;s disease dementia: which is more important?</article-title><source>Brain</source><year>2011</year><volume>134</volume><fpage>1493</fpage><lpage>1505</lpage><pub-id pub-id-type="doi">10.1093/brain/awr031</pub-id><pub-id pub-id-type="pmid">21596773</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Toledo</surname><given-names>JB</given-names></name><name><surname>Cairns</surname><given-names>NJ</given-names></name><name><surname>Da</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Carter</surname><given-names>D</given-names></name><name><surname>Fleisher</surname><given-names>A</given-names></name><name><surname>Householder</surname><given-names>E</given-names></name><name><surname>Ayutyanont</surname><given-names>N</given-names></name><name><surname>Roontiva</surname><given-names>A</given-names></name><name><surname>Bauer</surname><given-names>RJ</given-names></name><name><surname>Eisen</surname><given-names>P</given-names></name><name><surname>Shaw</surname><given-names>LM</given-names></name><name><surname>Davatzikos</surname><given-names>C</given-names></name><name><surname>Weiner</surname><given-names>MW</given-names></name><name><surname>Reiman</surname><given-names>EM</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><article-title>Clinical and multimodal biomarker correlates of ADNI neuropathological findings</article-title><source>Acta Neuropathol Commun</source><year>2013</year><volume>1</volume><fpage>65</fpage><pub-id pub-id-type="doi">10.1186/2051-5960-1-65</pub-id><pub-id pub-id-type="pmid">24252435</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>McKeith</surname><given-names>IG</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Lowe</surname><given-names>J</given-names></name><name><surname>Emre</surname><given-names>M</given-names></name><name><surname>O'Brien</surname><given-names>JT</given-names></name><name><surname>Feldman</surname><given-names>H</given-names></name><name><surname>Cummings</surname><given-names>J</given-names></name><name><surname>Duda</surname><given-names>JE</given-names></name><name><surname>Lippa</surname><given-names>C</given-names></name><name><surname>Perry</surname><given-names>EK</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Arai</surname><given-names>H</given-names></name><name><surname>Ballard</surname><given-names>CG</given-names></name><name><surname>Boeve</surname><given-names>B</given-names></name><name><surname>Burn</surname><given-names>DJ</given-names></name><name><surname>Costa</surname><given-names>D</given-names></name><name><surname>Del Ser</surname><given-names>T</given-names></name><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Gauthier</surname><given-names>S</given-names></name><name><surname>Goetz</surname><given-names>CG</given-names></name><name><surname>Gomez-Tortosa</surname><given-names>E</given-names></name><name><surname>Halliday</surname><given-names>G</given-names></name><name><surname>Hansen</surname><given-names>LA</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Iwatsubo</surname><given-names>T</given-names></name><name><surname>Kalaria</surname><given-names>RN</given-names></name><name><surname>Kaufer</surname><given-names>D</given-names></name><name><surname>Kenny</surname><given-names>RA</given-names></name><name><surname>Korczyn</surname><given-names>A</given-names></name><etal/><article-title>Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium</article-title><source>Neurology</source><year>2005</year><volume>65</volume><fpage>1863</fpage><lpage>1872</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000187889.17253.b1</pub-id><pub-id pub-id-type="pmid">16237129</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Molloy</surname><given-names>S</given-names></name><name><surname>McKeith</surname><given-names>IG</given-names></name><name><surname>O'Brien</surname><given-names>JT</given-names></name><name><surname>Burn</surname><given-names>DJ</given-names></name><article-title>The role of levodopa in the management of dementia with Lewy bodies</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2005</year><volume>76</volume><fpage>1200</fpage><lpage>1203</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2004.052332</pub-id><pub-id pub-id-type="pmid">16107351</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Bonelli</surname><given-names>SB</given-names></name><name><surname>Ransmayr</surname><given-names>G</given-names></name><name><surname>Steffelbauer</surname><given-names>M</given-names></name><name><surname>Lukas</surname><given-names>T</given-names></name><name><surname>Lampl</surname><given-names>C</given-names></name><name><surname>Deibl</surname><given-names>M</given-names></name><article-title>L-Dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia</article-title><source>Neurology</source><year>2004</year><volume>63</volume><fpage>376</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000130194.84594.96</pub-id><pub-id pub-id-type="pmid">15277644</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Feldman</surname><given-names>HH</given-names></name><name><surname>Jacova</surname><given-names>C</given-names></name><name><surname>Dekosky</surname><given-names>ST</given-names></name><name><surname>Barberger-Gateau</surname><given-names>P</given-names></name><name><surname>Cummings</surname><given-names>J</given-names></name><name><surname>Delacourte</surname><given-names>A</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Gauthier</surname><given-names>S</given-names></name><name><surname>Jicha</surname><given-names>G</given-names></name><name><surname>Meguro</surname><given-names>K</given-names></name><name><surname>O'Brien</surname><given-names>J</given-names></name><name><surname>Pasquier</surname><given-names>F</given-names></name><name><surname>Robert</surname><given-names>P</given-names></name><name><surname>Rossor</surname><given-names>M</given-names></name><name><surname>Salloway</surname><given-names>S</given-names></name><name><surname>Stern</surname><given-names>Y</given-names></name><name><surname>Visser</surname><given-names>PJ</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><article-title>Research criteria for the diagnosis of Alzheimer&#x02019;s disease: revising the NINCDS-ADRDA criteria</article-title><source>Lancet Neurol</source><year>2007</year><volume>6</volume><fpage>734</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(07)70178-3</pub-id><pub-id pub-id-type="pmid">17616482</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Weiner</surname><given-names>M</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><article-title>Cerebrospinal fluid and plasma biomarkers in Alzheimer disease</article-title><source>Nat Rev Neurol</source><year>2010</year><volume>6</volume><fpage>131</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2010.4</pub-id><pub-id pub-id-type="pmid">20157306</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Hansson</surname><given-names>O</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Buchhave</surname><given-names>P</given-names></name><name><surname>Londos</surname><given-names>E</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><article-title>Association between CSF biomarkers and incipient Alzheimer&#x02019;s disease in patients with mild cognitive impairment: a follow-up study</article-title><source>Lancet Neurol</source><year>2006</year><volume>5</volume><fpage>228</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(06)70355-6</pub-id><pub-id pub-id-type="pmid">16488378</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Buchhave</surname><given-names>P</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Wallin</surname><given-names>AK</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Hansson</surname><given-names>O</given-names></name><article-title>Cerebrospinal fluid levels of beta-amyloid 1&#x02013;42, but not of tau, are fully changed already 5 to 10&#x000a0;years before the onset of Alzheimer dementia</article-title><source>Arch Gen Psychiatry</source><year>2012</year><volume>69</volume><fpage>98</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2011.155</pub-id><pub-id pub-id-type="pmid">22213792</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Jellinger</surname><given-names>KA</given-names></name><article-title>Neurobiology of cognitive impairment in Parkinson&#x02019;s disease</article-title><source>Expert Rev Neurother</source><year>2012</year><volume>12</volume><fpage>1451</fpage><lpage>1466</lpage><pub-id pub-id-type="doi">10.1586/ern.12.131</pub-id><pub-id pub-id-type="pmid">23237352</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Mollenhauer</surname><given-names>B</given-names></name><name><surname>Schulz-Schaeffer</surname><given-names>W</given-names></name><name><surname>Schlossmacher</surname><given-names>M</given-names></name><article-title>Synaptic alpha-synuclein pathology as the likely cause of Parkinson&#x02019;s disease dementia</article-title><source>Lancet Neurol</source><year>2011</year><volume>10</volume><fpage>68</fpage><lpage>69</lpage></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Edison</surname><given-names>P</given-names></name><name><surname>Rowe</surname><given-names>CC</given-names></name><name><surname>Rinne</surname><given-names>JO</given-names></name><name><surname>Ng</surname><given-names>S</given-names></name><name><surname>Ahmed</surname><given-names>I</given-names></name><name><surname>Kemppainen</surname><given-names>N</given-names></name><name><surname>Villemagne</surname><given-names>VL</given-names></name><name><surname>O'Keefe</surname><given-names>G</given-names></name><name><surname>Nagren</surname><given-names>K</given-names></name><name><surname>Chaudhury</surname><given-names>KR</given-names></name><name><surname>Masters</surname><given-names>CL</given-names></name><name><surname>Brooks</surname><given-names>DJ</given-names></name><article-title>Amyloid load in Parkinson&#x02019;s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2008</year><volume>79</volume><fpage>1331</fpage><lpage>1338</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2007.127878</pub-id><pub-id pub-id-type="pmid">18653550</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Gomperts</surname><given-names>SN</given-names></name><name><surname>Rentz</surname><given-names>DM</given-names></name><name><surname>Moran</surname><given-names>E</given-names></name><name><surname>Becker</surname><given-names>JA</given-names></name><name><surname>Locascio</surname><given-names>JJ</given-names></name><name><surname>Klunk</surname><given-names>WE</given-names></name><name><surname>Mathis</surname><given-names>CA</given-names></name><name><surname>Elmaleh</surname><given-names>DR</given-names></name><name><surname>Shoup</surname><given-names>T</given-names></name><name><surname>Fischman</surname><given-names>AJ</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Growdon</surname><given-names>JH</given-names></name><name><surname>Johnson</surname><given-names>KA</given-names></name><article-title>Imaging amyloid deposition in Lewy body diseases</article-title><source>Neurology</source><year>2008</year><volume>71</volume><fpage>903</fpage><lpage>910</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000326146.60732.d6</pub-id><pub-id pub-id-type="pmid">18794492</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Jokinen</surname><given-names>P</given-names></name><name><surname>Scheinin</surname><given-names>N</given-names></name><name><surname>Aalto</surname><given-names>S</given-names></name><name><surname>Nagren</surname><given-names>K</given-names></name><name><surname>Savisto</surname><given-names>N</given-names></name><name><surname>Parkkola</surname><given-names>R</given-names></name><name><surname>Rokka</surname><given-names>J</given-names></name><name><surname>Haaparanta</surname><given-names>M</given-names></name><name><surname>Roytta</surname><given-names>M</given-names></name><name><surname>Rinne</surname><given-names>JO</given-names></name><article-title>[(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson&#x02019;s disease with and without dementia</article-title><source>Parkinsonism Relat Disord</source><year>2010</year><volume>16</volume><fpage>666</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2010.08.021</pub-id><pub-id pub-id-type="pmid">20870446</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Perry</surname><given-names>R</given-names></name><name><surname>Brown</surname><given-names>A</given-names></name><name><surname>Larsen</surname><given-names>JP</given-names></name><name><surname>Ballard</surname><given-names>C</given-names></name><article-title>Neuropathology of dementia in Parkinson&#x02019;s disease: a prospective, community-based study</article-title><source>Ann Neurol</source><year>2005</year><volume>58</volume><fpage>773</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1002/ana.20635</pub-id><pub-id pub-id-type="pmid">16240351</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Kramer</surname><given-names>ML</given-names></name><name><surname>Schulz-Schaeffer</surname><given-names>WJ</given-names></name><article-title>Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies</article-title><source>J Neurosci</source><year>2007</year><volume>27</volume><fpage>1405</fpage><lpage>1410</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4564-06.2007</pub-id><pub-id pub-id-type="pmid">17287515</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Gomperts</surname><given-names>SN</given-names></name><name><surname>Locascio</surname><given-names>JJ</given-names></name><name><surname>Marquie</surname><given-names>M</given-names></name><name><surname>Santarlasci</surname><given-names>AL</given-names></name><name><surname>Rentz</surname><given-names>DM</given-names></name><name><surname>Maye</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>KA</given-names></name><name><surname>Growdon</surname><given-names>JH</given-names></name><article-title>Brain amyloid and cognition in Lewy body diseases</article-title><source>Mov Disord</source><year>2012</year><volume>27</volume><fpage>965</fpage><lpage>973</lpage><pub-id pub-id-type="doi">10.1002/mds.25048</pub-id><pub-id pub-id-type="pmid">22693110</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Alves</surname><given-names>G</given-names></name><name><surname>Bronnick</surname><given-names>K</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Ballard</surname><given-names>C</given-names></name><name><surname>Kurz</surname><given-names>MW</given-names></name><name><surname>Andreasson</surname><given-names>U</given-names></name><name><surname>Tysnes</surname><given-names>OB</given-names></name><name><surname>Larsen</surname><given-names>JP</given-names></name><name><surname>Mulugeta</surname><given-names>E</given-names></name><article-title>CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson&#x02019;s disease: the Norwegian ParkWest study</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2010</year><volume>81</volume><fpage>1080</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2009.199950</pub-id><pub-id pub-id-type="pmid">20547614</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Compta</surname><given-names>Y</given-names></name><name><surname>Marti</surname><given-names>MJ</given-names></name><name><surname>Ibarretxe-Bilbao</surname><given-names>N</given-names></name><name><surname>Junque</surname><given-names>C</given-names></name><name><surname>Valldeoriola</surname><given-names>F</given-names></name><name><surname>Munoz</surname><given-names>E</given-names></name><name><surname>Ezquerra</surname><given-names>M</given-names></name><name><surname>Rios</surname><given-names>J</given-names></name><name><surname>Tolosa</surname><given-names>E</given-names></name><article-title>Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson&#x02019;s disease</article-title><source>Mov Disord</source><year>2009</year><volume>24</volume><fpage>2203</fpage><lpage>2210</lpage><pub-id pub-id-type="doi">10.1002/mds.22594</pub-id><pub-id pub-id-type="pmid">19795497</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Montine</surname><given-names>TJ</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Quinn</surname><given-names>JF</given-names></name><name><surname>Peskind</surname><given-names>ER</given-names></name><name><surname>Craft</surname><given-names>S</given-names></name><name><surname>Ginghina</surname><given-names>C</given-names></name><name><surname>Chung</surname><given-names>KA</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Galasko</surname><given-names>DR</given-names></name><name><surname>Jankovic</surname><given-names>J</given-names></name><name><surname>Zabetian</surname><given-names>CP</given-names></name><name><surname>Leverenz</surname><given-names>JB</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><article-title>CSF Abeta(42) and tau in Parkinson&#x02019;s disease with cognitive impairment</article-title><source>Mov Disord</source><year>2010</year><volume>25</volume><fpage>2682</fpage><lpage>2685</lpage><pub-id pub-id-type="doi">10.1002/mds.23287</pub-id><pub-id pub-id-type="pmid">20818673</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Gomperts</surname><given-names>SN</given-names></name><name><surname>Locascio</surname><given-names>JJ</given-names></name><name><surname>Rentz</surname><given-names>D</given-names></name><name><surname>Santarlasci</surname><given-names>A</given-names></name><name><surname>Marquie</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>KA</given-names></name><name><surname>Growdon</surname><given-names>JH</given-names></name><article-title>Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia</article-title><source>Neurology</source><year>2013</year><volume>80</volume><fpage>85</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e31827b1a07</pub-id><pub-id pub-id-type="pmid">23243071</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Alves</surname><given-names>G</given-names></name><name><surname>Lange</surname><given-names>J</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Andreasson</surname><given-names>U</given-names></name><name><surname>Forland</surname><given-names>MG</given-names></name><name><surname>Tysnes</surname><given-names>OB</given-names></name><name><surname>Larsen</surname><given-names>JP</given-names></name><name><surname>Pedersen</surname><given-names>KF</given-names></name><article-title>CSF Abeta42 predicts early-onset dementia in Parkinson disease</article-title><source>Neurology</source><year>2014</year><volume>82</volume><fpage>1784</fpage><lpage>1790</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000000425</pub-id><pub-id pub-id-type="pmid">24748671</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Borroni</surname><given-names>B</given-names></name><name><surname>Alberici</surname><given-names>A</given-names></name><name><surname>Archetti</surname><given-names>S</given-names></name><name><surname>Magnani</surname><given-names>E</given-names></name><name><surname>Di Luca</surname><given-names>M</given-names></name><name><surname>Padovani</surname><given-names>A</given-names></name><article-title>New insights into biological markers of frontotemporal lobar degeneration spectrum</article-title><source>Curr Med Chem</source><year>2010</year><volume>17</volume><fpage>1002</fpage><lpage>1009</lpage><pub-id pub-id-type="doi">10.2174/092986710790820651</pub-id><pub-id pub-id-type="pmid">20156164</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Mak</surname><given-names>E</given-names></name><name><surname>Su</surname><given-names>L</given-names></name><name><surname>Williams</surname><given-names>GB</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>JT</given-names></name><article-title>Neuroimaging characteristics of dementia with Lewy bodies</article-title><source>Alzheimers Res Ther</source><year>2014</year><volume>6</volume><fpage>18</fpage><pub-id pub-id-type="doi">10.1186/alzrt248</pub-id><pub-id pub-id-type="pmid">25031634</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Bonanni</surname><given-names>L</given-names></name><name><surname>Thomas</surname><given-names>A</given-names></name><name><surname>Tiraboschi</surname><given-names>P</given-names></name><name><surname>Perfetti</surname><given-names>B</given-names></name><name><surname>Varanese</surname><given-names>S</given-names></name><name><surname>Onofrj</surname><given-names>M</given-names></name><article-title>EEG comparisons in early Alzheimer&#x02019;s disease, dementia with Lewy bodies and Parkinson&#x02019;s disease with dementia patients with a 2-year follow-up</article-title><source>Brain</source><year>2008</year><volume>131</volume><fpage>690</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1093/brain/awm322</pub-id><pub-id pub-id-type="pmid">18202105</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Terzaghi</surname><given-names>M</given-names></name><name><surname>Arnaldi</surname><given-names>D</given-names></name><name><surname>Rizzetti</surname><given-names>MC</given-names></name><name><surname>Minafra</surname><given-names>B</given-names></name><name><surname>Cremascoli</surname><given-names>R</given-names></name><name><surname>Rustioni</surname><given-names>V</given-names></name><name><surname>Zangaglia</surname><given-names>R</given-names></name><name><surname>Pasotti</surname><given-names>C</given-names></name><name><surname>Sinforiani</surname><given-names>E</given-names></name><name><surname>Pacchetti</surname><given-names>C</given-names></name><name><surname>Manni</surname><given-names>R</given-names></name><article-title>Analysis of video-polysomnographic sleep findings in dementia with Lewy bodies</article-title><source>Mov Disord</source><year>2013</year><volume>28</volume><fpage>1416</fpage><lpage>1423</lpage><pub-id pub-id-type="pmid">23744574</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>de Vos</surname><given-names>RAI</given-names></name><name><surname>Bohl</surname><given-names>J</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name><article-title>Gastric [alpha]-synuclein immunoreactive inclusions in Meissner&#x02019;s and Auerbach&#x02019;s plexuses in cases staged for Parkinson&#x02019;s disease-related brain pathology</article-title><source>Neurosci Lett</source><year>2006</year><volume>396</volume><fpage>67</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2005.11.012</pub-id><pub-id pub-id-type="pmid">16330147</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Devic</surname><given-names>I</given-names></name><name><surname>Hwang</surname><given-names>H</given-names></name><name><surname>Edgar</surname><given-names>JS</given-names></name><name><surname>Izutsu</surname><given-names>K</given-names></name><name><surname>Presland</surname><given-names>R</given-names></name><name><surname>Pan</surname><given-names>C</given-names></name><name><surname>Goodlett</surname><given-names>DR</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Armaly</surname><given-names>J</given-names></name><name><surname>Tumas</surname><given-names>V</given-names></name><name><surname>Zabetian</surname><given-names>CP</given-names></name><name><surname>Leverenz</surname><given-names>JB</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><article-title>Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson&#x02019;s disease</article-title><source>Brain</source><year>2011</year><volume>134</volume><fpage>e178</fpage><pub-id pub-id-type="doi">10.1093/brain/awr015</pub-id><pub-id pub-id-type="pmid">21349902</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Glenner</surname><given-names>GG</given-names></name><name><surname>Wong</surname><given-names>CW</given-names></name><name><surname>Quaranta</surname><given-names>V</given-names></name><name><surname>Eanes</surname><given-names>ED</given-names></name><article-title>The amyloid deposits in Alzheimer&#x02019;s disease: their nature and pathogenesis</article-title><source>Appl Pathol</source><year>1984</year><volume>2</volume><fpage>357</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">6242724</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Guntert</surname><given-names>A</given-names></name><name><surname>Dobeli</surname><given-names>H</given-names></name><name><surname>Bohrmann</surname><given-names>B</given-names></name><article-title>High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain</article-title><source>Neuroscience</source><year>2006</year><volume>143</volume><fpage>461</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2006.08.027</pub-id><pub-id pub-id-type="pmid">17008022</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Jendroska</surname><given-names>K</given-names></name><name><surname>Kashiwagi</surname><given-names>M</given-names></name><name><surname>Sassoon</surname><given-names>J</given-names></name><name><surname>Daniel</surname><given-names>SE</given-names></name><article-title>Amyloid beta-peptide and its relationship with dementia in Lewy body disease</article-title><source>J Neural Transm Suppl</source><year>1997</year><volume>51</volume><fpage>137</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1007/978-3-7091-6846-2_11</pub-id><pub-id pub-id-type="pmid">9470134</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Kanemaru</surname><given-names>K</given-names></name><name><surname>Kameda</surname><given-names>N</given-names></name><name><surname>Yamanouchi</surname><given-names>H</given-names></name><article-title>Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies</article-title><source>Neurology</source><year>2000</year><volume>54</volume><fpage>1875</fpage><lpage>1876</lpage><pub-id pub-id-type="doi">10.1212/WNL.54.9.1875</pub-id><pub-id pub-id-type="pmid">10802808</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Fagan</surname><given-names>AM</given-names></name><name><surname>Mintun</surname><given-names>MA</given-names></name><name><surname>Mach</surname><given-names>RH</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Dence</surname><given-names>CS</given-names></name><name><surname>Shah</surname><given-names>AR</given-names></name><name><surname>LaRossa</surname><given-names>GN</given-names></name><name><surname>Spinner</surname><given-names>ML</given-names></name><name><surname>Klunk</surname><given-names>WE</given-names></name><name><surname>Mathis</surname><given-names>CA</given-names></name><name><surname>DeKosky</surname><given-names>ST</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><article-title>Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans</article-title><source>Ann Neurol</source><year>2006</year><volume>59</volume><fpage>512</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1002/ana.20730</pub-id><pub-id pub-id-type="pmid">16372280</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Mollenhauer</surname><given-names>B</given-names></name><name><surname>Esselmann</surname><given-names>H</given-names></name><name><surname>Roeber</surname><given-names>S</given-names></name><name><surname>Schulz-Schaeffer</surname><given-names>WJ</given-names></name><name><surname>Trenkwalder</surname><given-names>C</given-names></name><name><surname>Bibl</surname><given-names>M</given-names></name><name><surname>Steinacker</surname><given-names>P</given-names></name><name><surname>Kretzschmar</surname><given-names>HA</given-names></name><name><surname>Wiltfang</surname><given-names>J</given-names></name><name><surname>Otto</surname><given-names>M</given-names></name><article-title>Different CSF beta-amyloid processing in Alzheimer&#x02019;s and Creutzfeldt-Jakob disease</article-title><source>J Neural Transm</source><year>2011</year><volume>118</volume><fpage>691</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1007/s00702-010-0543-z</pub-id><pub-id pub-id-type="pmid">21210287</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Nutu</surname><given-names>M</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Londos</surname><given-names>E</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><name><surname>Nagga</surname><given-names>K</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Hansson</surname><given-names>O</given-names></name><name><surname>Ohrfelt</surname><given-names>A</given-names></name><article-title>Evaluation of the cerebrospinal fluid amyloid-beta1-42/amyloid-beta1-40 ratio measured by alpha-LISA to distinguish Alzheimer&#x02019;s disease from other dementia disorders</article-title><source>Dement Geriatr Cogn Disord</source><year>2013</year><volume>36</volume><fpage>99</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1159/000353442</pub-id><pub-id pub-id-type="pmid">23860354</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Vanderstichele</surname><given-names>H</given-names></name><name><surname>De Vreese</surname><given-names>K</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Andreasen</surname><given-names>N</given-names></name><name><surname>Sindic</surname><given-names>C</given-names></name><name><surname>Ivanoiu</surname><given-names>A</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Burger</surname><given-names>K</given-names></name><name><surname>Parnetti</surname><given-names>L</given-names></name><name><surname>Lanari</surname><given-names>A</given-names></name><name><surname>Padovani</surname><given-names>A</given-names></name><name><surname>DiLuca</surname><given-names>M</given-names></name><name><surname>Blaser</surname><given-names>M</given-names></name><name><surname>Olsson</surname><given-names>AO</given-names></name><name><surname>Pottel</surname><given-names>H</given-names></name><name><surname>Hulstaert</surname><given-names>F</given-names></name><name><surname>Vanmechelen</surname><given-names>E</given-names></name><article-title>Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer&#x02019;s disease and dementia with Lewy bodies</article-title><source>Clin Chem Lab Med</source><year>2006</year><volume>44</volume><fpage>1472</fpage><lpage>1480</lpage><pub-id pub-id-type="doi">10.1515/CCLM.2006.258</pub-id><pub-id pub-id-type="pmid">17163825</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Mollenhauer</surname><given-names>B</given-names></name><name><surname>Bibl</surname><given-names>M</given-names></name><name><surname>Wiltfang</surname><given-names>J</given-names></name><name><surname>Steinacker</surname><given-names>P</given-names></name><name><surname>Ciesielczyk</surname><given-names>B</given-names></name><name><surname>Neubert</surname><given-names>K</given-names></name><name><surname>Trenkwalder</surname><given-names>C</given-names></name><name><surname>Otto</surname><given-names>M</given-names></name><article-title>Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1&#x02013;42), and beta-amyloid(1&#x02013;40) in cerebrospinal fluid of patients with dementia with Lewy bodies</article-title><source>Clin Chem Lab Med</source><year>2006</year><volume>44</volume><fpage>192</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1515/CCLM.2006.035</pub-id><pub-id pub-id-type="pmid">16475906</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>Clark</surname><given-names>CM</given-names></name><name><surname>Xie</surname><given-names>S</given-names></name><name><surname>Chittams</surname><given-names>J</given-names></name><name><surname>Ewbank</surname><given-names>D</given-names></name><name><surname>Peskind</surname><given-names>E</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>McKeel</surname><given-names>DW</given-names><suffix>Jr</suffix></name><name><surname>Farlow</surname><given-names>M</given-names></name><name><surname>Weitlauf</surname><given-names>SL</given-names></name><name><surname>Quinn</surname><given-names>J</given-names></name><name><surname>Kaye</surname><given-names>J</given-names></name><name><surname>Knopman</surname><given-names>D</given-names></name><name><surname>Arai</surname><given-names>H</given-names></name><name><surname>Doody</surname><given-names>RS</given-names></name><name><surname>DeCarli</surname><given-names>C</given-names></name><name><surname>Leight</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><article-title>Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?</article-title><source>Arch Neurol</source><year>2003</year><volume>60</volume><fpage>1696</fpage><lpage>1702</lpage><pub-id pub-id-type="doi">10.1001/archneur.60.12.1696</pub-id><pub-id pub-id-type="pmid">14676043</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>Slaets</surname><given-names>S</given-names></name><name><surname>Le Bastard</surname><given-names>N</given-names></name><name><surname>Theuns</surname><given-names>J</given-names></name><name><surname>Sleegers</surname><given-names>K</given-names></name><name><surname>Verstraeten</surname><given-names>A</given-names></name><name><surname>De Leenheir</surname><given-names>E</given-names></name><name><surname>Luyckx</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>JJ</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name><name><surname>Engelborghs</surname><given-names>S</given-names></name><article-title>Amyloid pathology influences abeta1-42 cerebrospinal fluid levels in dementia with lewy bodies</article-title><source>J Alzheimers Dis</source><year>2013</year><volume>35</volume><fpage>137</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">23364139</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><name><surname>Bibl</surname><given-names>M</given-names></name><name><surname>Mollenhauer</surname><given-names>B</given-names></name><name><surname>Lewczuk</surname><given-names>P</given-names></name><name><surname>Esselmann</surname><given-names>H</given-names></name><name><surname>Wolf</surname><given-names>S</given-names></name><name><surname>Trenkwalder</surname><given-names>C</given-names></name><name><surname>Otto</surname><given-names>M</given-names></name><name><surname>Stiens</surname><given-names>G</given-names></name><name><surname>Ruther</surname><given-names>E</given-names></name><name><surname>Kornhuber</surname><given-names>J</given-names></name><name><surname>Wiltfang</surname><given-names>J</given-names></name><article-title>Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias</article-title><source>Mol Psychiatry</source><year>2007</year><volume>12</volume><fpage>671</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1038/sj.mp.4001967</pub-id><pub-id pub-id-type="pmid">17339876</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><name><surname>Mollenhauer</surname><given-names>B</given-names></name><name><surname>Esselmann</surname><given-names>H</given-names></name><name><surname>Trenkwalder</surname><given-names>C</given-names></name><name><surname>Schulz-Schaeffer</surname><given-names>W</given-names></name><name><surname>Kretzschmar</surname><given-names>H</given-names></name><name><surname>Otto</surname><given-names>M</given-names></name><name><surname>Wiltfang</surname><given-names>J</given-names></name><name><surname>Bibl</surname><given-names>M</given-names></name><article-title>CSF amyloid-beta peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer&#x02019;s disease</article-title><source>J Alzheimers Dis</source><year>2011</year><volume>24</volume><fpage>383</fpage><lpage>391</lpage><pub-id pub-id-type="pmid">21297274</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Brinkmalm</surname><given-names>G</given-names></name><name><surname>Tran</surname><given-names>AJ</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Westman-Brinkmalm</surname><given-names>A</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><article-title>Identification of novel APP/Abeta isoforms in human cerebrospinal fluid</article-title><source>Neurodegener Dis</source><year>2009</year><volume>6</volume><fpage>87</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1159/000203774</pub-id><pub-id pub-id-type="pmid">19229112</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><name><surname>Cleveland</surname><given-names>DW</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name><name><surname>Kirschner</surname><given-names>MW</given-names></name><article-title>Conservation of microtubule associated proteins. Isolation and characterization of tau and the high molecular weight microtubule associated protein from chicken brain and from mouse fibroblasts and comparison to the corresponding mammalian brain proteins</article-title><source>J Biol Chem</source><year>1979</year><volume>254</volume><fpage>12670</fpage><lpage>12678</lpage><pub-id pub-id-type="pmid">227904</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Braak</surname><given-names>E</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><name><surname>Iqbal</surname><given-names>K</given-names></name><article-title>Occurrence of neuropil threads in the senile human brain and in Alzheimer&#x02019;s disease: a third location of paired helical filaments outside of neurofibrillary tangles and neuritic plaques</article-title><source>Neurosci Lett</source><year>1986</year><volume>65</volume><fpage>351</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1016/0304-3940(86)90288-0</pub-id><pub-id pub-id-type="pmid">2423928</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><name><surname>Iqbal</surname><given-names>K</given-names></name><name><surname>Quinlan</surname><given-names>M</given-names></name><name><surname>Tung</surname><given-names>YC</given-names></name><name><surname>Zaidi</surname><given-names>MS</given-names></name><name><surname>Wisniewski</surname><given-names>HM</given-names></name><article-title>Microtubule-associated protein tau. A component of Alzheimer paired helical filaments</article-title><source>J Biol Chem</source><year>1986</year><volume>261</volume><fpage>6084</fpage><lpage>6089</lpage><pub-id pub-id-type="pmid">3084478</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>VM</given-names></name><name><surname>Goedert</surname><given-names>M</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><article-title>Neurodegenerative tauopathies</article-title><source>Annu Rev Neurosci</source><year>2001</year><volume>24</volume><fpage>1121</fpage><lpage>1159</lpage><pub-id pub-id-type="doi">10.1146/annurev.neuro.24.1.1121</pub-id><pub-id pub-id-type="pmid">11520930</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><name><surname>Mollenhauer</surname><given-names>B</given-names></name><name><surname>Cepek</surname><given-names>L</given-names></name><name><surname>Bibl</surname><given-names>M</given-names></name><name><surname>Wiltfang</surname><given-names>J</given-names></name><name><surname>Schulz-Schaeffer</surname><given-names>WJ</given-names></name><name><surname>Ciesielczyk</surname><given-names>B</given-names></name><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Steinacker</surname><given-names>P</given-names></name><name><surname>Kretzschmar</surname><given-names>HA</given-names></name><name><surname>Poser</surname><given-names>S</given-names></name><name><surname>Trenkwalder</surname><given-names>C</given-names></name><name><surname>Otto</surname><given-names>M</given-names></name><article-title>Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies</article-title><source>Dement Geriatr Cogn Disord</source><year>2005</year><volume>19</volume><fpage>164</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1159/000083178</pub-id><pub-id pub-id-type="pmid">15637452</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><name><surname>Parnetti</surname><given-names>L</given-names></name><name><surname>Lanari</surname><given-names>A</given-names></name><name><surname>Amici</surname><given-names>S</given-names></name><name><surname>Gallai</surname><given-names>V</given-names></name><name><surname>Vanmechelen</surname><given-names>E</given-names></name><name><surname>Hulstaert</surname><given-names>F</given-names></name><article-title>CSF phosphorylated tau is a possible marker for discriminating Alzheimer&#x02019;s disease from dementia with Lewy bodies. Phospho-Tau International Study Group</article-title><source>Neurol Sci</source><year>2001</year><volume>22</volume><fpage>77</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1007/s100720170055</pub-id><pub-id pub-id-type="pmid">11487210</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><name><surname>Merdes</surname><given-names>AR</given-names></name><name><surname>Hansen</surname><given-names>LA</given-names></name><name><surname>Jeste</surname><given-names>DV</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Hofstetter</surname><given-names>CR</given-names></name><name><surname>Ho</surname><given-names>GJ</given-names></name><name><surname>Thal</surname><given-names>LJ</given-names></name><name><surname>Corey-Bloom</surname><given-names>J</given-names></name><article-title>Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies</article-title><source>Neurology</source><year>2003</year><volume>60</volume><fpage>1586</fpage><lpage>1590</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000065889.42856.F2</pub-id><pub-id pub-id-type="pmid">12771246</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><name><surname>Arima</surname><given-names>K</given-names></name><name><surname>Hirai</surname><given-names>S</given-names></name><name><surname>Sunohara</surname><given-names>N</given-names></name><name><surname>Aoto</surname><given-names>K</given-names></name><name><surname>Izumiyama</surname><given-names>Y</given-names></name><name><surname>Ueda</surname><given-names>K</given-names></name><name><surname>Ikeda</surname><given-names>K</given-names></name><name><surname>Kawai</surname><given-names>M</given-names></name><article-title>Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson&#x02019;s disease and in dementia with Lewy bodies</article-title><source>Brain Res</source><year>1999</year><volume>843</volume><fpage>53</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/S0006-8993(99)01848-X</pub-id><pub-id pub-id-type="pmid">10528110</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Goernitz</surname><given-names>A</given-names></name><name><surname>Buerger</surname><given-names>K</given-names></name><article-title>Advances in the development of biomarkers for Alzheimer&#x02019;s disease: from CSF total tau and Abeta(1&#x02013;42) proteins to phosphorylated tau protein</article-title><source>Brain Res Bull</source><year>2003</year><volume>61</volume><fpage>243</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1016/S0361-9230(03)00087-X</pub-id><pub-id pub-id-type="pmid">12909294</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Wallin</surname><given-names>A</given-names></name><name><surname>Agren</surname><given-names>H</given-names></name><name><surname>Spenger</surname><given-names>C</given-names></name><name><surname>Siegfried</surname><given-names>J</given-names></name><name><surname>Vanmechelen</surname><given-names>E</given-names></name><article-title>Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?</article-title><source>Mol Chem Neuropathol</source><year>1995</year><volume>26</volume><fpage>231</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1007/BF02815140</pub-id><pub-id pub-id-type="pmid">8748926</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><name><surname>Buerger</surname><given-names>K</given-names></name><name><surname>Zinkowski</surname><given-names>R</given-names></name><name><surname>Teipel</surname><given-names>SJ</given-names></name><name><surname>Tapiola</surname><given-names>T</given-names></name><name><surname>Arai</surname><given-names>H</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Andreasen</surname><given-names>N</given-names></name><name><surname>Hofmann-Kiefer</surname><given-names>K</given-names></name><name><surname>DeBernardis</surname><given-names>J</given-names></name><name><surname>Kerkman</surname><given-names>D</given-names></name><name><surname>McCulloch</surname><given-names>C</given-names></name><name><surname>Kohnken</surname><given-names>R</given-names></name><name><surname>Padberg</surname><given-names>F</given-names></name><name><surname>Pirttila</surname><given-names>T</given-names></name><name><surname>Schapiro</surname><given-names>MB</given-names></name><name><surname>Rapoport</surname><given-names>SI</given-names></name><name><surname>Moller</surname><given-names>HJ</given-names></name><name><surname>Davies</surname><given-names>P</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><article-title>Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231</article-title><source>Arch Neurol</source><year>2002</year><volume>59</volume><fpage>1267</fpage><lpage>1272</lpage><pub-id pub-id-type="doi">10.1001/archneur.59.8.1267</pub-id><pub-id pub-id-type="pmid">12164722</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><name><surname>Hu</surname><given-names>YY</given-names></name><name><surname>He</surname><given-names>SS</given-names></name><name><surname>Wang</surname><given-names>XC</given-names></name><name><surname>Duan</surname><given-names>QH</given-names></name><name><surname>Khatoon</surname><given-names>S</given-names></name><name><surname>Iqbal</surname><given-names>K</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><name><surname>Wang</surname><given-names>JZ</given-names></name><article-title>Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients</article-title><source>Neurosci Lett</source><year>2002</year><volume>320</volume><fpage>156</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/S0304-3940(02)00047-2</pub-id><pub-id pub-id-type="pmid">11852185</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><name><surname>Itoh</surname><given-names>N</given-names></name><name><surname>Arai</surname><given-names>H</given-names></name><name><surname>Urakami</surname><given-names>K</given-names></name><name><surname>Ishiguro</surname><given-names>K</given-names></name><name><surname>Ohno</surname><given-names>H</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Buerger</surname><given-names>K</given-names></name><name><surname>Wiltfang</surname><given-names>J</given-names></name><name><surname>Otto</surname><given-names>M</given-names></name><name><surname>Kretzschmar</surname><given-names>H</given-names></name><name><surname>Moeller</surname><given-names>HJ</given-names></name><name><surname>Imagawa</surname><given-names>M</given-names></name><name><surname>Kohno</surname><given-names>H</given-names></name><name><surname>Nakashima</surname><given-names>K</given-names></name><name><surname>Kuzuhara</surname><given-names>S</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Imahori</surname><given-names>K</given-names></name><article-title>Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer&#x02019;s disease</article-title><source>Ann Neurol</source><year>2001</year><volume>50</volume><fpage>150</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1002/ana.1054</pub-id><pub-id pub-id-type="pmid">11506396</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><name><surname>Chandra</surname><given-names>S</given-names></name><name><surname>Gallardo</surname><given-names>G</given-names></name><name><surname>Fernandez-Chacon</surname><given-names>R</given-names></name><name><surname>Schluter</surname><given-names>OM</given-names></name><name><surname>Sudhof</surname><given-names>TC</given-names></name><article-title>Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration</article-title><source>Cell</source><year>2005</year><volume>123</volume><fpage>383</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.09.028</pub-id><pub-id pub-id-type="pmid">16269331</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><name><surname>Spillantini</surname><given-names>MG</given-names></name><name><surname>Schmidt</surname><given-names>ML</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Jakes</surname><given-names>R</given-names></name><name><surname>Goedert</surname><given-names>M</given-names></name><article-title>Alpha-synuclein in Lewy bodies</article-title><source>Nature</source><year>1997</year><volume>388</volume><fpage>839</fpage><lpage>840</lpage><pub-id pub-id-type="doi">10.1038/42166</pub-id><pub-id pub-id-type="pmid">9278044</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><name><surname>Gai</surname><given-names>WP</given-names></name><name><surname>Power</surname><given-names>JH</given-names></name><name><surname>Blumbergs</surname><given-names>PC</given-names></name><name><surname>Blessing</surname><given-names>WW</given-names></name><article-title>Multiple-system atrophy: a new alpha-synuclein disease?</article-title><source>Lancet</source><year>1998</year><volume>352</volume><fpage>547</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)79256-4</pub-id><pub-id pub-id-type="pmid">9716068</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><name><surname>El-Agnaf</surname><given-names>OM</given-names></name><name><surname>Salem</surname><given-names>SA</given-names></name><name><surname>Paleologou</surname><given-names>KE</given-names></name><name><surname>Cooper</surname><given-names>LJ</given-names></name><name><surname>Fullwood</surname><given-names>NJ</given-names></name><name><surname>Gibson</surname><given-names>MJ</given-names></name><name><surname>Curran</surname><given-names>MD</given-names></name><name><surname>Court</surname><given-names>JA</given-names></name><name><surname>Mann</surname><given-names>DM</given-names></name><name><surname>Ikeda</surname><given-names>S</given-names></name><name><surname>Cookson</surname><given-names>MR</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Allsop</surname><given-names>D</given-names></name><article-title>Alpha-synuclein implicated in Parkinson&#x02019;s disease is present in extracellular biological fluids, including human plasma</article-title><source>Faseb J</source><year>2003</year><volume>17</volume><fpage>1945</fpage><lpage>1947</lpage><pub-id pub-id-type="pmid">14519670</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><article-title>Intravesicular localization and exocytosis of alpha-synuclein and its aggregates</article-title><source>J Neurosci</source><year>2005</year><volume>25</volume><fpage>6016</fpage><lpage>6024</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0692-05.2005</pub-id><pub-id pub-id-type="pmid">15976091</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Bradner</surname><given-names>J</given-names></name><name><surname>Hancock</surname><given-names>AM</given-names></name><name><surname>Chung</surname><given-names>KA</given-names></name><name><surname>Quinn</surname><given-names>JF</given-names></name><name><surname>Peskind</surname><given-names>ER</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Jankovic</surname><given-names>J</given-names></name><name><surname>Zabetian</surname><given-names>CP</given-names></name><name><surname>Kim</surname><given-names>HM</given-names></name><name><surname>Leverenz</surname><given-names>JB</given-names></name><name><surname>Montine</surname><given-names>TJ</given-names></name><name><surname>Ginghina</surname><given-names>C</given-names></name><name><surname>Kang</surname><given-names>UJ</given-names></name><name><surname>Cain</surname><given-names>KC</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Aasly</surname><given-names>J</given-names></name><name><surname>Goldstein</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><article-title>Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression</article-title><source>Ann Neurol</source><year>2011</year><volume>69</volume><fpage>570</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1002/ana.22311</pub-id><pub-id pub-id-type="pmid">21400565</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><name><surname>Aerts</surname><given-names>MB</given-names></name><name><surname>Esselink</surname><given-names>RA</given-names></name><name><surname>Abdo</surname><given-names>WF</given-names></name><name><surname>Bloem</surname><given-names>BR</given-names></name><name><surname>Verbeek</surname><given-names>MM</given-names></name><article-title>CSF alpha-synuclein does not differentiate between parkinsonian disorders</article-title><source>Neurobiol Aging</source><year>2011</year><volume>33</volume><fpage>430.e1-3</fpage><pub-id pub-id-type="pmid">21236518</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><name><surname>Mollenhauer</surname><given-names>B</given-names></name><name><surname>El-Agnaf</surname><given-names>OM</given-names></name><name><surname>Marcus</surname><given-names>K</given-names></name><name><surname>Trenkwalder</surname><given-names>C</given-names></name><name><surname>Schlossmacher</surname><given-names>MG</given-names></name><article-title>Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies</article-title><source>Biomark Med</source><year>2010</year><volume>4</volume><fpage>683</fpage><lpage>699</lpage><pub-id pub-id-type="doi">10.2217/bmm.10.90</pub-id><pub-id pub-id-type="pmid">20945981</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><name><surname>Kapaki</surname><given-names>E</given-names></name><name><surname>Paraskevas</surname><given-names>GP</given-names></name><name><surname>Emmanouilidou</surname><given-names>E</given-names></name><name><surname>Vekrellis</surname><given-names>K</given-names></name><article-title>The diagnostic value of CSF alpha-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer&#x02019;s disease</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e81654</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0081654</pub-id><pub-id pub-id-type="pmid">24282614</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><name><surname>Cantuti-Castelvetri</surname><given-names>I</given-names></name><name><surname>Klucken</surname><given-names>J</given-names></name><name><surname>Ingelsson</surname><given-names>M</given-names></name><name><surname>Ramasamy</surname><given-names>K</given-names></name><name><surname>McLean</surname><given-names>PJ</given-names></name><name><surname>Frosch</surname><given-names>MP</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Standaert</surname><given-names>DG</given-names></name><article-title>Alpha-synuclein and chaperones in dementia with Lewy bodies</article-title><source>J Neuropathol Exp Neurol</source><year>2005</year><volume>64</volume><fpage>1058</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1097/01.jnen.0000190063.90440.69</pub-id><pub-id pub-id-type="pmid">16319716</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><name><surname>Beyer</surname><given-names>K</given-names></name><name><surname>Humbert</surname><given-names>J</given-names></name><name><surname>Ferrer</surname><given-names>A</given-names></name><name><surname>Lao</surname><given-names>JI</given-names></name><name><surname>Carrato</surname><given-names>C</given-names></name><name><surname>Lopez</surname><given-names>D</given-names></name><name><surname>Ferrer</surname><given-names>I</given-names></name><name><surname>Ariza</surname><given-names>A</given-names></name><article-title>Low alpha-synuclein 126 mRNA levels in dementia with Lewy bodies and Alzheimer disease</article-title><source>Neuroreport</source><year>2006</year><volume>17</volume><fpage>1327</fpage><lpage>1330</lpage><pub-id pub-id-type="doi">10.1097/01.wnr.0000224773.66904.e7</pub-id><pub-id pub-id-type="pmid">16951579</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><name><surname>Anderson</surname><given-names>JP</given-names></name><name><surname>Walker</surname><given-names>DE</given-names></name><name><surname>Goldstein</surname><given-names>JM</given-names></name><name><surname>de Laat</surname><given-names>R</given-names></name><name><surname>Banducci</surname><given-names>K</given-names></name><name><surname>Caccavello</surname><given-names>RJ</given-names></name><name><surname>Barbour</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Kling</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Diep</surname><given-names>L</given-names></name><name><surname>Keim</surname><given-names>PS</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Chataway</surname><given-names>T</given-names></name><name><surname>Schlossmacher</surname><given-names>MG</given-names></name><name><surname>Seubert</surname><given-names>P</given-names></name><name><surname>Schenk</surname><given-names>D</given-names></name><name><surname>Sinha</surname><given-names>S</given-names></name><name><surname>Gai</surname><given-names>WP</given-names></name><name><surname>Chilcote</surname><given-names>TJ</given-names></name><article-title>Phosphorylation of Ser 129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease</article-title><source>J Biol Chem</source><year>2006</year><volume>281</volume><fpage>29739</fpage><lpage>29752</lpage><pub-id pub-id-type="doi">10.1074/jbc.M600933200</pub-id><pub-id pub-id-type="pmid">16847063</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><name><surname>Chodobski</surname><given-names>A</given-names></name><name><surname>Szmydynger-Chodobska</surname><given-names>J</given-names></name><article-title>Choroid plexus: target for polypeptides and site of their synthesis</article-title><source>Microsc Res Tech</source><year>2001</year><volume>52</volume><fpage>65</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1002/1097-0029(20010101)52:1&#x0003c;65::AID-JEMT9&#x0003e;3.0.CO;2-4</pub-id><pub-id pub-id-type="pmid">11135450</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><name><surname>Toledo</surname><given-names>JB</given-names></name><name><surname>Korff</surname><given-names>A</given-names></name><name><surname>Shaw</surname><given-names>LM</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><article-title>CSF alpha-synuclein improves diagnostic and prognostic performance of CSF tau and Abeta in Alzheimer&#x02019;s disease</article-title><source>Acta Neuropathol</source><year>2013</year><volume>126</volume><fpage>683</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1007/s00401-013-1148-z</pub-id><pub-id pub-id-type="pmid">23812319</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><name><surname>Mattsson</surname><given-names>N</given-names></name><name><surname>Insel</surname><given-names>P</given-names></name><name><surname>Tosun</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Weiner</surname><given-names>M</given-names></name><article-title>Effects of baseline CSF alpha-synuclein on regional brain atrophy rates in healthy elders, mild cognitive impairment and Alzheimer&#x02019;s disease</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e85443</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0085443</pub-id><pub-id pub-id-type="pmid">24392009</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><name><surname>El-Agnaf</surname><given-names>OM</given-names></name><name><surname>Salem</surname><given-names>SA</given-names></name><name><surname>Paleologou</surname><given-names>KE</given-names></name><name><surname>Curran</surname><given-names>MD</given-names></name><name><surname>Gibson</surname><given-names>MJ</given-names></name><name><surname>Court</surname><given-names>JA</given-names></name><name><surname>Schlossmacher</surname><given-names>MG</given-names></name><name><surname>Allsop</surname><given-names>D</given-names></name><article-title>Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson&#x02019;s disease</article-title><source>Faseb J</source><year>2006</year><volume>20</volume><fpage>419</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1096/fj.03-1449com</pub-id><pub-id pub-id-type="pmid">16507759</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><name><surname>Tokuda</surname><given-names>T</given-names></name><name><surname>Qureshi</surname><given-names>MM</given-names></name><name><surname>Ardah</surname><given-names>MT</given-names></name><name><surname>Varghese</surname><given-names>S</given-names></name><name><surname>Shehab</surname><given-names>SA</given-names></name><name><surname>Kasai</surname><given-names>T</given-names></name><name><surname>Ishigami</surname><given-names>N</given-names></name><name><surname>Tamaoka</surname><given-names>A</given-names></name><name><surname>Nakagawa</surname><given-names>M</given-names></name><name><surname>El-Agnaf</surname><given-names>OM</given-names></name><article-title>Detection of elevated levels of {alpha}-synuclein oligomers in CSF from patients with Parkinson disease</article-title><source>Neurology</source><year>2010</year><volume>75</volume><fpage>1766</fpage><lpage>1772</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181fd613b</pub-id><pub-id pub-id-type="pmid">20962290</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><name><surname>Wennstrom</surname><given-names>M</given-names></name><name><surname>Surova</surname><given-names>Y</given-names></name><name><surname>Hall</surname><given-names>S</given-names></name><name><surname>Nilsson</surname><given-names>C</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><name><surname>Bostrom</surname><given-names>F</given-names></name><name><surname>Hansson</surname><given-names>O</given-names></name><name><surname>Nielsen</surname><given-names>HM</given-names></name><article-title>Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e53250</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0053250</pub-id><pub-id pub-id-type="pmid">23308173</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><name><surname>Waragai</surname><given-names>M</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Fujita</surname><given-names>M</given-names></name><name><surname>Nakai</surname><given-names>M</given-names></name><name><surname>Ho</surname><given-names>GJ</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Akatsu</surname><given-names>H</given-names></name><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Hashimoto</surname><given-names>M</given-names></name><article-title>Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson&#x02019;s disease</article-title><source>Biochem Biophys Res Commun</source><year>2006</year><volume>345</volume><fpage>967</fpage><lpage>972</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2006.05.011</pub-id><pub-id pub-id-type="pmid">16707095</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><name><surname>Hong</surname><given-names>Z</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Chung</surname><given-names>KA</given-names></name><name><surname>Quinn</surname><given-names>JF</given-names></name><name><surname>Peskind</surname><given-names>ER</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Jankovic</surname><given-names>J</given-names></name><name><surname>Zabetian</surname><given-names>CP</given-names></name><name><surname>Leverenz</surname><given-names>JB</given-names></name><name><surname>Baird</surname><given-names>G</given-names></name><name><surname>Montine</surname><given-names>TJ</given-names></name><name><surname>Hancock</surname><given-names>AM</given-names></name><name><surname>Hwang</surname><given-names>H</given-names></name><name><surname>Pan</surname><given-names>C</given-names></name><name><surname>Bradner</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>UJ</given-names></name><name><surname>Jensen</surname><given-names>PH</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><article-title>DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson&#x02019;s disease</article-title><source>Brain</source><year>2010</year><volume>133</volume><fpage>713</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1093/brain/awq008</pub-id><pub-id pub-id-type="pmid">20157014</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><name><surname>Choi</surname><given-names>J</given-names></name><name><surname>Sullards</surname><given-names>MC</given-names></name><name><surname>Olzmann</surname><given-names>JA</given-names></name><name><surname>Rees</surname><given-names>HD</given-names></name><name><surname>Weintraub</surname><given-names>ST</given-names></name><name><surname>Bostwick</surname><given-names>DE</given-names></name><name><surname>Gearing</surname><given-names>M</given-names></name><name><surname>Levey</surname><given-names>AI</given-names></name><name><surname>Chin</surname><given-names>LS</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><article-title>Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases</article-title><source>J Biol Chem</source><year>2006</year><volume>281</volume><fpage>10816</fpage><lpage>10824</lpage><pub-id pub-id-type="doi">10.1074/jbc.M509079200</pub-id><pub-id pub-id-type="pmid">16517609</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><name><surname>de Jong</surname><given-names>D</given-names></name><name><surname>Jansen</surname><given-names>RW</given-names></name><name><surname>Pijnenburg</surname><given-names>YA</given-names></name><name><surname>van Geel</surname><given-names>WJ</given-names></name><name><surname>Borm</surname><given-names>GF</given-names></name><name><surname>Kremer</surname><given-names>HP</given-names></name><name><surname>Verbeek</surname><given-names>MM</given-names></name><article-title>CSF neurofilament proteins in the differential diagnosis of dementia</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2007</year><volume>78</volume><fpage>936</fpage><lpage>938</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2006.107326</pub-id><pub-id pub-id-type="pmid">17314187</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><name><surname>Ching</surname><given-names>GY</given-names></name><name><surname>Liem</surname><given-names>RK</given-names></name><article-title>Assembly of type IV neuronal intermediate filaments in nonneuronal cells in the absence of preexisting cytoplasmic intermediate filaments</article-title><source>J Cell Biol</source><year>1993</year><volume>122</volume><fpage>1323</fpage><lpage>1335</lpage><pub-id pub-id-type="doi">10.1083/jcb.122.6.1323</pub-id><pub-id pub-id-type="pmid">8376465</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><name><surname>Schmidt</surname><given-names>ML</given-names></name><name><surname>Murray</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><name><surname>Hill</surname><given-names>WD</given-names></name><name><surname>Wertkin</surname><given-names>A</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><article-title>Epitope map of neurofilament protein domains in cortical and peripheral nervous system Lewy bodies</article-title><source>Am J Pathol</source><year>1991</year><volume>139</volume><fpage>53</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">1713021</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><name><surname>Storch</surname><given-names>J</given-names></name><name><surname>Thumser</surname><given-names>AE</given-names></name><article-title>Tissue-specific functions in the fatty acid-binding protein family</article-title><source>J Biol Chem</source><year>2010</year><volume>285</volume><fpage>32679</fpage><lpage>32683</lpage><pub-id pub-id-type="doi">10.1074/jbc.R110.135210</pub-id><pub-id pub-id-type="pmid">20716527</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><name><surname>Cheon</surname><given-names>MS</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Fountoulakis</surname><given-names>M</given-names></name><name><surname>Lubec</surname><given-names>G</given-names></name><article-title>Heart type fatty acid binding protein (H-FABP) is decreased in brains of patients with Down syndrome and Alzheimer&#x02019;s disease</article-title><source>J Neural Transm Suppl</source><year>2003</year><volume>67</volume><fpage>225</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1007/978-3-7091-6721-2_20</pub-id><pub-id pub-id-type="pmid">15068254</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><name><surname>Steinacker</surname><given-names>P</given-names></name><name><surname>Mollenhauer</surname><given-names>B</given-names></name><name><surname>Bibl</surname><given-names>M</given-names></name><name><surname>Cepek</surname><given-names>L</given-names></name><name><surname>Esselmann</surname><given-names>H</given-names></name><name><surname>Brechlin</surname><given-names>P</given-names></name><name><surname>Lewczuk</surname><given-names>P</given-names></name><name><surname>Poser</surname><given-names>S</given-names></name><name><surname>Kretzschmar</surname><given-names>HA</given-names></name><name><surname>Wiltfang</surname><given-names>J</given-names></name><name><surname>Trenkwalder</surname><given-names>C</given-names></name><name><surname>Otto</surname><given-names>M</given-names></name><article-title>Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases</article-title><source>Neurosci Lett</source><year>2004</year><volume>370</volume><fpage>36</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2004.07.061</pub-id><pub-id pub-id-type="pmid">15489013</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><name><surname>Mollenhauer</surname><given-names>B</given-names></name><name><surname>Steinacker</surname><given-names>P</given-names></name><name><surname>Bahn</surname><given-names>E</given-names></name><name><surname>Bibl</surname><given-names>M</given-names></name><name><surname>Brechlin</surname><given-names>P</given-names></name><name><surname>Schlossmacher</surname><given-names>MG</given-names></name><name><surname>Locascio</surname><given-names>JJ</given-names></name><name><surname>Wiltfang</surname><given-names>J</given-names></name><name><surname>Kretzschmar</surname><given-names>HA</given-names></name><name><surname>Poser</surname><given-names>S</given-names></name><name><surname>Trenkwalder</surname><given-names>C</given-names></name><name><surname>Otto</surname><given-names>M</given-names></name><article-title>Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies</article-title><source>Neurodegener Dis</source><year>2007</year><volume>4</volume><fpage>366</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1159/000105157</pub-id><pub-id pub-id-type="pmid">17622779</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><name><surname>Aerts</surname><given-names>MB</given-names></name><name><surname>Esselink</surname><given-names>RA</given-names></name><name><surname>Claassen</surname><given-names>JA</given-names></name><name><surname>Abdo</surname><given-names>WF</given-names></name><name><surname>Bloem</surname><given-names>BR</given-names></name><name><surname>Verbeek</surname><given-names>MM</given-names></name><article-title>CSF tau, Abeta42, and MHPG differentiate dementia with Lewy bodies from Alzheimer&#x02019;s disease</article-title><source>J Alzheimers Dis</source><year>2011</year><volume>27</volume><fpage>377</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">21841257</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><name><surname>Herbert</surname><given-names>MK</given-names></name><name><surname>Aerts</surname><given-names>MB</given-names></name><name><surname>Kuiperij</surname><given-names>HB</given-names></name><name><surname>Claassen</surname><given-names>JA</given-names></name><name><surname>Spies</surname><given-names>PE</given-names></name><name><surname>Esselink</surname><given-names>RA</given-names></name><name><surname>Bloem</surname><given-names>BR</given-names></name><name><surname>Verbeek</surname><given-names>MM</given-names></name><article-title>Addition of MHPG to Alzheimer&#x02019;s disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer&#x02019;s disease but not other dementias</article-title><source>Alzheimers Dement</source><year>2014</year><volume>10</volume><fpage>448</fpage><lpage>455</lpage><comment>e442</comment><pub-id pub-id-type="doi">10.1016/j.jalz.2013.05.1775</pub-id><pub-id pub-id-type="pmid">24239248</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><name><surname>Nielsen</surname><given-names>HM</given-names></name><name><surname>Hall</surname><given-names>S</given-names></name><name><surname>Surova</surname><given-names>Y</given-names></name><name><surname>Nagga</surname><given-names>K</given-names></name><name><surname>Nilsson</surname><given-names>C</given-names></name><name><surname>Londos</surname><given-names>E</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><name><surname>Hansson</surname><given-names>O</given-names></name><name><surname>Wennstrom</surname><given-names>M</given-names></name><article-title>Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies</article-title><source>J Alzheimers Dis</source><year>2014</year><volume>40</volume><fpage>343</fpage><lpage>350</lpage><pub-id pub-id-type="pmid">24448788</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><name><surname>Schultz</surname><given-names>K</given-names></name><name><surname>Wiehager</surname><given-names>S</given-names></name><name><surname>Nilsson</surname><given-names>K</given-names></name><name><surname>Nielsen</surname><given-names>JE</given-names></name><name><surname>Lindquist</surname><given-names>SG</given-names></name><name><surname>Hjermind</surname><given-names>LE</given-names></name><name><surname>Andersen</surname><given-names>BB</given-names></name><name><surname>Wallin</surname><given-names>A</given-names></name><name><surname>Nilsson</surname><given-names>C</given-names></name><name><surname>Petersen</surname><given-names>A</given-names></name><article-title>Reduced CSF CART in dementia with Lewy bodies</article-title><source>Neurosci Lett</source><year>2009</year><volume>453</volume><fpage>104</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2009.02.008</pub-id><pub-id pub-id-type="pmid">19356602</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><name><surname>Bostrom</surname><given-names>F</given-names></name><name><surname>Hansson</surname><given-names>O</given-names></name><name><surname>Gerhardsson</surname><given-names>L</given-names></name><name><surname>Lundh</surname><given-names>T</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><name><surname>Stomrud</surname><given-names>E</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Londos</surname><given-names>E</given-names></name><article-title>CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies</article-title><source>Neurobiol Aging</source><year>2009</year><volume>30</volume><fpage>1265</fpage><lpage>1271</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2007.10.018</pub-id><pub-id pub-id-type="pmid">18191875</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><name><surname>Ho</surname><given-names>GJ</given-names></name><name><surname>Liang</surname><given-names>W</given-names></name><name><surname>Waragai</surname><given-names>M</given-names></name><name><surname>Sekiyama</surname><given-names>K</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Hashimoto</surname><given-names>M</given-names></name><article-title>Bridging molecular genetics and biomarkers in lewy body and related disorders</article-title><source>Int J Alzheimers Dis</source><year>2011</year><volume>2011</volume><fpage>842475</fpage><pub-id pub-id-type="pmid">21760990</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><name><surname>Wada-Isoe</surname><given-names>K</given-names></name><name><surname>Michio</surname><given-names>K</given-names></name><name><surname>Imamura</surname><given-names>K</given-names></name><name><surname>Nakaso</surname><given-names>K</given-names></name><name><surname>Kusumi</surname><given-names>M</given-names></name><name><surname>Kowa</surname><given-names>H</given-names></name><name><surname>Nakashima</surname><given-names>K</given-names></name><article-title>Serum proteomic profiling of dementia with Lewy bodies: diagnostic potential of SELDI-TOF MS analysis</article-title><source>J Neural Transm</source><year>2007</year><volume>114</volume><fpage>1579</fpage><lpage>1583</lpage><pub-id pub-id-type="doi">10.1007/s00702-007-0794-5</pub-id><pub-id pub-id-type="pmid">17690946</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><name><surname>Abdi</surname><given-names>F</given-names></name><name><surname>Quinn</surname><given-names>JF</given-names></name><name><surname>Jankovic</surname><given-names>J</given-names></name><name><surname>McIntosh</surname><given-names>M</given-names></name><name><surname>Leverenz</surname><given-names>JB</given-names></name><name><surname>Peskind</surname><given-names>E</given-names></name><name><surname>Nixon</surname><given-names>R</given-names></name><name><surname>Nutt</surname><given-names>J</given-names></name><name><surname>Chung</surname><given-names>K</given-names></name><name><surname>Zabetian</surname><given-names>C</given-names></name><name><surname>Samii</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>M</given-names></name><name><surname>Hattan</surname><given-names>S</given-names></name><name><surname>Pan</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>GJ</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Waichunas</surname><given-names>D</given-names></name><name><surname>Montine</surname><given-names>TJ</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><article-title>Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders</article-title><source>J Alzheimers Dis</source><year>2006</year><volume>9</volume><fpage>293</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">16914840</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>J</given-names></name><article-title>Proteomics of human cerebrospinal fluid - the good, the bad, and the ugly</article-title><source>Proteomics Clin Appl</source><year>2007</year><volume>1</volume><fpage>805</fpage><lpage>819</lpage><pub-id pub-id-type="doi">10.1002/prca.200700081</pub-id><pub-id pub-id-type="pmid">21136735</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><name><surname>Mollenhauer</surname><given-names>B</given-names></name><name><surname>Schlossmacher</surname><given-names>MG</given-names></name><article-title>CSF synuclein: adding to the biomarker footprint of dementia with Lewy bodies</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2010</year><volume>81</volume><fpage>590</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2010.206391</pub-id><pub-id pub-id-type="pmid">20522867</pub-id></mixed-citation></ref></ref-list></back></article>